The most significant step would be to guarantee continued funding to reimburse insurers for waiving deductibles and co-payments for low-income customers, as the health law requires companies to do. The Trump administration has threatened to stop making the payments; insurers are now getting them on a month-to-month basis. Democratic leaders in Congress identified rising drug prices as one of their economic priorities in a new campaign, “A Better Deal,” that was made public this past week. And Dr. Scott Gottlieb, the new commissioner of the Food and Drug Administration, is taking steps to encourage more competition among generic manufacturers. Some may be reconsidering now that repeal of the health law seems unlikely.

Source: New York Times July 29, 2017 22:04 UTC